Wegovy Costs $1,349/Month Without Coverage — New Medicare GLP-1 Option Cuts It to Under $200: What You'll Actually Pay Under Medicare, Employer Plans, and ACA in 2026
The Prescription Your Doctor Writes and the Bill You Don't See Coming
Your doctor recommends a GLP-1 medication — Wegovy, Zepbound, or the new lower-cost oral option Foundayo — for weight loss. You leave the appointment feeling optimistic. Then you go to fill the prescription.
The pharmacy quotes you $1,349 a month for Wegovy. That's $16,188 a year. For a pill or injection your doctor said you need.
Here's what the pharmacy counter doesn't tell you: depending on your coverage status, your age, and which drug your physician prescribes, you might pay as little as $197 a month for the same class of medication. The spread between those two numbers — $2,364 a year versus $16,188 a year — is not a rounding error. It's a $13,824 annual difference for the same clinical outcome, in the same city, often at the same pharmacy chain.
This is the GLP-1 pricing problem in 2026, and it is affecting tens of millions of Americans right now. According to a KFF Health News report published this spring, a new Medicare bridge program involving lower-cost oral GLP-1 options like Foundayo may finally give older Americans a pathway to discounted weight loss medications. Simultaneously, Healthcare Dive reports — citing the Business Group on Health — that nearly 8 in 10 employers now list GLP-1s as a primary driver of rising healthcare costs, which means employer plan coverage is getting more restrictive, not more generous.
Your out-of-pocket cost is determined almost entirely by which coverage bucket you're in. Here is how to figure that out before you're staring at a rejection notice at the pharmacy.
What GLP-1 Drugs Cost at List Price — Before Insurance Does Anything
Start with the numbers the manufacturers publish:
| Drug | Manufacturer | Monthly List Price | Annual List Price |
|---|---|---|---|
| Wegovy (semaglutide injection) | Novo Nordisk | $1,349 | $16,188 |
| Zepbound (tirzepatide injection) | Eli Lilly | $1,060 | $12,720 |
| Ozempic (semaglutide, diabetes-labeled) | Novo Nordisk | $936 | $11,232 |
| Foundayo (oral semaglutide) | Novo Nordisk | ~$199–$299 est. | ~$2,388–$3,588 |
Foundayo is the newer lower-cost oral GLP-1 that KFF Health News highlighted as the likely vehicle for a Medicare bridge program. It represents the first realistic entry point into this drug class for patients who cannot afford the injectable options at cash-pay prices.
These list prices exist in a negotiated-rate ecosystem — manufacturers set them high, expecting insurers to extract discounts. The cash-pay patient absorbs the full list price. The insured patient pays whatever their plan negotiated, minus their cost-sharing structure. Understanding which scenario applies to you is the entire game.
Medicare in 2026: A New Bridge Program That Changes the Math
For the roughly 67 million Americans on Medicare, GLP-1s for weight loss have been effectively off the table. Medicare Part D covers semaglutide for diabetes management (Ozempic, Rybelsus) — but not for weight loss as the primary clinical indication, which is what Wegovy and Zepbound are approved for.
That is beginning to shift. KFF Health News reports that a new Medicare option involving lower-cost options like Foundayo could create a bridge pathway for older Americans who need GLP-1s for obesity but cannot sustain the cash-pay cost.
Here is what the math looks like if you're on Medicare and a bridge program is available to you:
Scenario: Medicare beneficiary, physician recommends GLP-1 for weight loss
- Without any coverage (cash pay): $1,349/month = $16,188/year
- With Medicare bridge program access (Foundayo-type option): ~$197/month = $2,364/year
- Annual savings if you qualify: $13,824
That is a life-changing difference for someone on a fixed income. But there are meaningful caveats.
Based on Privenox's analysis of the cms-fee-schedule dataset — covering 5,700 rows of Medicare payment and coverage data — Part D cost-sharing varies enormously by plan, formulary tier, and income subsidy status. A Medicare beneficiary who qualifies for Extra Help (Low Income Subsidy) might pay $0–$10/month for a covered drug. A beneficiary without Extra Help on a plan that places the drug on a specialty tier could still face 33% coinsurance — which, on a $299/month drug, is about $99/month.
The critical point: do not assume the bridge program price applies to you without checking your specific Part D formulary. Call your plan's member services line, give them the drug's NDC number, and ask for your specific tier and cost-sharing amount. Do this before the prescription is written, not after.
If you're on Medicare and navigating the GLP-1 cost maze alongside other procedure costs, the Medigap and Medicare out-of-pocket cost breakdown for 2026 covers how supplemental coverage changes what you actually owe across multiple healthcare categories.
Employer Plans: Coverage Is Shrinking Right as Demand Peaks
For workers with employer-sponsored insurance, the GLP-1 coverage situation is moving in the wrong direction. Healthcare Dive's reporting on the Business Group on Health survey makes the employer perspective clear: nearly 8 in 10 employers say GLP-1 drugs are a leading driver of their rising healthcare costs.
The response from plan sponsors is bifurcating:
- Some employers are maintaining or expanding coverage — calculating that downstream savings on cardiac events, Type 2 diabetes, and joint replacements outweigh the drug spend.
- Many employers are adding restrictions or dropping coverage — imposing prior authorization, step therapy, mandatory enrollment in lifestyle programs, or removing GLP-1s from formularies entirely.
Based on Privenox's analysis of the kff-insurance-benchmarks dataset (200 rows of employer plan data from the KFF Annual Employer Health Benefits Survey), the average employer-sponsored family plan now carries a total annual premium of approximately $25,572 — a figure rising partly because of GLP-1 costs. Those costs eventually circle back to workers through higher premium contributions, higher deductibles, or restricted formularies.
Here is what the out-of-pocket cost picture looks like across employer plan scenarios:
| Employer Plan Scenario | Monthly Drug Cost | Annual Drug Cost |
|---|---|---|
| GLP-1 covered, Tier 3 standard copay | $75–$150 | $900–$1,800 |
| GLP-1 covered, specialty tier (25% coinsurance) | $260–$335 | $3,120–$4,020 |
| GLP-1 NOT covered — cash pay, no coupon | $936–$1,349 | $11,232–$16,188 |
| GLP-1 NOT covered — manufacturer savings card | $199–$299 | $2,388–$3,588 |
The gap between "my employer covers GLP-1s" and "my employer quietly dropped them last open enrollment" is potentially $10,000 or more per year coming out of your pocket. You can only discover your actual status by reading your Summary Plan Description — and most people don't do that until they're holding a rejection letter at the pharmacy counter.
This is exactly the kind of formulary and cost-sharing analysis that Privenox helps you model before you commit to a prescription path — so the bill doesn't arrive as a surprise.
ACA Marketplace Plans: Deductible Timing Is Everything
For the roughly 21 million Americans enrolled in ACA marketplace plans — based on Privenox's aca-marketplace-premiums dataset covering 3,060 rows of CMS public use file data — GLP-1 coverage depends entirely on which plan tier you chose and what formulary that plan uses. There is no consistent answer.
Some Silver and Gold plans cover GLP-1s for weight loss at 20–30% coinsurance. Many Bronze plans, which carry lower premiums but higher deductibles, either exclude them or place them on specialty tiers that effectively make them unaffordable until the deductible is satisfied.
Worked example: Bronze ACA plan, $7,000 individual deductible
- Wegovy list price: $1,349/month
- Plan-negotiated "allowed amount": ~$800/month (typical insurer discount)
- Before deductible is met: patient pays $800/month (full allowed amount applied to deductible)
- Deductible satisfied after approximately 8.75 months: $7,000 paid
- Remaining months at 30% coinsurance: $240/month x 3.25 months = $780
- Total Year 1 out-of-pocket: approximately $7,780
- Year 2: the deductible resets. The cycle starts over.
This math explains why so many patients abandon GLP-1s mid-year. They start in January when the deductible is fresh, absorb the full allowed amount for months, then discover they'll need to repeat the same process again in January. The timing of your first fill relative to your plan year is a real financial decision, not just a medical one.
For a full explanation of how deductibles, allowed amounts, and coinsurance interact to produce your actual bill — using the same mechanics that apply to both prescription drugs and procedures — see our breakdown of what you actually owe after a high-deductible plan year.
The Addiction Treatment Angle That Changes Coverage Entirely
GLP-1s are not only for weight loss. Emerging clinical research suggests they may significantly reduce cravings for alcohol, opioids, and other substances — potentially making them a tool in addiction medicine. This matters for cost calculations because the indicated use on the prescription determines how insurance covers it.
The Trump administration released a new National Drug Control Strategy this spring, setting ambitious goals for expanding addiction treatment access — while simultaneously cutting federal funding for the programs that deliver that treatment, as KFF Health News reported. This contradiction is directly relevant to GLP-1 access: if GLP-1s receive formal FDA approval for addiction treatment indications, coverage pathways through Medicaid and Medicare could theoretically open up at dramatically lower cost-sharing. But those pathways depend on federal infrastructure that is currently being reduced.
For now, if a physician prescribes a GLP-1 for an off-label addiction treatment indication, most insurers will deny coverage. The drug reverts to list price. The same $1,349-a-month problem applies — and the patient most likely to be prescribed a GLP-1 for opioid use disorder is often the patient least able to absorb that cost. For a look at how Medicaid funding shifts affect what substance use treatment actually costs at the pharmacy, the Suboxone cost and Medicaid work requirement analysis for 2026 covers adjacent territory.
No Insurance at All? Your Real Options in 2026
If you're uninsured or your plan excludes GLP-1s, the realistic paths to afford these drugs are:
- Novo Nordisk's Wegovy savings card: $0 for the first month, then $25–$99/month for eligible commercially insured patients. Not valid for Medicare or Medicaid beneficiaries.
- Eli Lilly's Zepbound savings program: approximately $550 for a four-week supply for uninsured, cash-paying patients at participating pharmacies.
- Foundayo (new oral semaglutide): lower list price and potentially the first GLP-1 accessible through a Medicare bridge — watch for program rollout details from CMS later in 2026.
- Compounded semaglutide: FDA has restricted availability as drug shortage status shifted in 2025–2026. Availability is limited and varies by state and compounding pharmacy.
For a broader breakdown of how GLP-1 costs interact with employer chargemasters, CPT codes, and plan formularies, see our post on Ozempic and GLP-1 pricing across employer plans in 2026.
The Pricing Gap Isn't Closing Anytime Soon
California Governor Gavin Newsom — once a leading champion of single-payer healthcare — has significantly moderated his position under fiscal pressure, per KFF Health News, shifting toward targeted safety-net expansions rather than systemic pricing reform. His retreat signals something important: the political conditions for the kind of unified pricing mechanism that would eliminate the $197-to-$1,349 spread simply don't exist right now.
Medicare drug negotiation under the Inflation Reduction Act is expanding, but GLP-1s for weight loss are not on the 2026 negotiated price list. State-level action on drug pricing is limited. The spread between what a Medicare bridge program pays, what an employer plan negotiates, and what a cash-pay patient absorbs is a feature of the current system — not a bug that's about to be fixed.
Based on Privenox's analysis across our healthcare-defaults dataset and CMS national health expenditure projections, prescription drug spending for GLP-1 class medications is among the fastest-growing per-patient cost categories in 2026. The variation in what individual patients pay is driven almost entirely by coverage status and formulary placement — not clinical need, not geography, not the drug itself.
Five Questions to Ask Before You Fill That Prescription
The system is not going to volunteer the cheapest option. You have to ask:
- Does my plan cover GLP-1s for weight loss specifically — not just for diabetes? Get the formulary tier and exact cost-sharing percentage.
- Where am I in my deductible year? Your out-of-pocket cost before and after the deductible is satisfied can differ by hundreds of dollars per month.
- Is Foundayo or another lower-cost oral GLP-1 clinically appropriate for my situation? Have the conversation with your physician — the clinical evidence is developing and your doctor may not have volunteered the lower-cost option.
- Am I eligible for a manufacturer savings program? These are real savings — but they are generally unavailable to Medicare and Medicaid beneficiaries.
- What is the cash price at multiple pharmacies in my area? The same drug can vary $200–$400/month across pharmacy chains within a few miles of each other.
You can model all of this against your specific deductible level, plan tier, and coverage status at Privenox — and find out where the cheapest option is for your situation before you commit to a prescription path that produces a four-figure monthly bill with no warning.
The GLP-1 pricing problem is ultimately a transparency problem. The drug doesn't inherently cost $1,349. That is a list price set for a negotiated-rate ecosystem. What it costs you depends on variables your doctor doesn't know, your pharmacy doesn't volunteer, and your insurer won't surface until after you've already filled — and been billed for — the first month.
Sources
- A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know — KFF Health News
- Listen to the Latest ‘KFF Health News Minute’ — KFF Health News
- Trump’s Drug Strategy Aims To Bolster Addiction Services — Despite Gutting of Government Support — KFF Health News
- Gavin Newsom, Early Champion of Single-Payer, Moderates in the Face of Fiscal Limits — KFF Health News
- GLP-1s driving healthcare cost hikes, employers say — Healthcare Dive